514 related articles for article (PubMed ID: 29397400)
1. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
[TBL] [Abstract][Full Text] [Related]
3. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
4. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
5. The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a.
Han D; Wang Y; Wang Y; Dai X; Zhou T; Chen J; Tao B; Zhang J; Cao F
Circ Res; 2020 Jul; 127(4):e108-e125. PubMed ID: 32392088
[TBL] [Abstract][Full Text] [Related]
6. microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes.
Gryshkova V; Lushbough I; Palmer J; Burrier R; Delaunois A; Donley E; Valentin JP
Arch Toxicol; 2022 Jul; 96(7):2033-2047. PubMed ID: 35488128
[TBL] [Abstract][Full Text] [Related]
7. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
8. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.
Maillet A; Tan KP; Brunham LR
Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443
[TBL] [Abstract][Full Text] [Related]
9. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
Hsu WT; Huang CY; Yen CYT; Cheng AL; Hsieh PCH
Theranostics; 2018; 8(12):3176-3188. PubMed ID: 29930721
[No Abstract] [Full Text] [Related]
10. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1α and LDHA.
Hu D; Linders A; Yamak A; Correia C; Kijlstra JD; Garakani A; Xiao L; Milan DJ; van der Meer P; Serra M; Alves PM; Domian IJ
Circ Res; 2018 Oct; 123(9):1066-1079. PubMed ID: 30355156
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-129-1-3p protects cardiomyocytes from pirarubicin-induced apoptosis by down-regulating the GRIN2D-mediated Ca
Li Q; Qin M; Tan Q; Li T; Gu Z; Huang P; Ren L
J Cell Mol Med; 2020 Feb; 24(3):2260-2271. PubMed ID: 31957170
[TBL] [Abstract][Full Text] [Related]
13. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4.
Golforoush PA; Narasimhan P; Chaves-Guerrero PP; Lawrence E; Newton G; Yan R; Harding SE; Perrior T; Chapman KL; Schneider MD
Sci Rep; 2020 Jul; 10(1):12060. PubMed ID: 32694738
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
Sachinidis A
Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
[TBL] [Abstract][Full Text] [Related]
15. Modelling cadmium-induced cardiotoxicity using human pluripotent stem cell-derived cardiomyocytes.
Shen J; Wang X; Zhou D; Li T; Tang L; Gong T; Su J; Liang P
J Cell Mol Med; 2018 Sep; 22(9):4221-4235. PubMed ID: 29993192
[TBL] [Abstract][Full Text] [Related]
16. High-Content Electrophysiological Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes (hPSC-CMs).
Kong CW; Geng L; Li RA
Methods Mol Biol; 2018; 1722():185-194. PubMed ID: 29264806
[TBL] [Abstract][Full Text] [Related]
17. Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning.
Yang H; Zhong W; Hamidi MR; Zhou G; Liu C
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1041-1048. PubMed ID: 31518384
[TBL] [Abstract][Full Text] [Related]
18. Increasing the physical size and nucleation status of human pluripotent stem cell-derived ventricular cardiomyocytes by cell fusion.
Kong CW; Chen S; Geng L; Shum AM; Sun D; Li RA
Stem Cell Res; 2017 Mar; 19():76-81. PubMed ID: 28086122
[TBL] [Abstract][Full Text] [Related]
19. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
[TBL] [Abstract][Full Text] [Related]
20. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
Tan SH; Ye L
J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
